Tag: Long acting injection

The time it takes for paliperidone to leave your body varies dramatically depending on the formulation, ranging from a few days for the oral tablet to over a year for some long-acting injectable versions. Understanding the specific pharmacokinetics of your medication is key to managing its effects.

Approximately 1 in 100 people worldwide are affected by schizophrenia, a serious mental health condition requiring continuous management. The drug **Trevicta** is a long-acting injectable medication designed for the maintenance treatment of schizophrenia, offering a less frequent dosing schedule for stable adult patients.

Paliperidone injections are a crucial, long-acting treatment option for millions of adults with schizophrenia and schizoaffective disorder, offering the benefit of consistent medication delivery over time. For those undergoing this treatment, understanding **how is paliperidone injection given?** is essential to feel informed and prepared for the procedure.

Nearly half of American adults with high blood pressure do not have it under control with traditional daily medication. A promising development is zilebesiran, a new injection for hypertension currently in advanced clinical trials, which could offer patients sustained blood pressure control with just a twice-yearly dose.

In a clinical trial, 85% of people treated with INVEGA SUSTENNA for schizoaffective disorder did not have a relapse of their symptoms for 15 months. So, **what does the Invega injection help with** and why is it a vital long-term treatment option for serious mental health conditions?

Trevicta is an antipsychotic medication that contains the active substance paliperidone, which is a metabolite of risperidone. In the European Union, it is marketed as a prolonged-release injection, used for the maintenance treatment of adult schizophrenia patients who are already stable on a once-monthly injectable version of the same medication.

According to clinical studies, long-acting injectable antipsychotics, such as Xeplion, have been shown to significantly reduce the rate of relapse in adults with schizophrenia. What is xeplion injection, and how does this monthly treatment work to manage symptoms and improve the lives of those with mental health conditions like schizophrenia and schizoaffective disorder?.

Lenacapavir is a first-in-class, long-acting HIV capsid inhibitor administered as a twice-yearly injection, a significant advancement in HIV care. Understanding who qualifies for lenacapavir is crucial, as eligibility depends on its intended use for either prevention (PrEP) or treating multi-drug resistant HIV.

On December 22, 2022, the FDA approved Sunlenca (lenacapavir), a groundbreaking, long-acting medication for heavily treatment-experienced adults living with multidrug-resistant HIV-1. This first-in-class capsid inhibitor offers a twice-yearly subcutaneous injection, revolutionizing treatment options for those with limited alternatives.

Named the "Breakthrough of the Year" by *Science* magazine in 2024, lenacapavir is a first-in-class, long-acting medication used for both the treatment of multi-drug resistant HIV and for pre-exposure prophylaxis (PrEP). It is a capsid inhibitor that acts on the virus in multiple stages of its lifecycle, a novel approach compared to older antiretroviral therapies.